Pulsed Field Ablation With Concomitant Radiofrequency Cardioneuroablation in Patients With Paroxysmal Atrial Fibrillation

NCT ID: NCT07171463

Last Updated: 2025-09-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-26

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pulsed-field ablation (PFA) is a novel, non-thermal method for the treatment of atrial fibrillation (AF). It uses short, high-voltage electrical pulses to selectively ablate cardiomyocytes. PFA has demonstrated a high safety profile with reduced complication rates compared to thermal ablation.

Thermal ablation of parasympathetic ganglia during conventional pulmonary vein isolation (PVI) may improve long-term procedural outcomes by reducing AF recurrence. However, due to its non-thermal nature, PFA may not significantly affect cardiac autonomic innervation, which could be clinically relevant in vagally mediated AF or tachycardia-bradycardia syndrome.

This randomized study compares two strategies: (1) PFA-only PVI, and (2) PFA combined with selective thermal ablation (radiofrequency energy) of the superior paraseptal parasympathetic ganglion. The primary objective is to evaluate whether adjunctive thermal ablation improves clinical outcomes and reduces intraprocedural bradyarrhythmic events.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation (Paroxysmal)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PFA with selective thermal ganglion ablation

Participants will undergo pulmonary vein isolation using a point-by-point bipolar pulsed-field ablation. In addition, selective thermal ablation using radiofrequency energy will be performed at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical region of the superior paraseptal parasympathetic ganglion.

Group Type EXPERIMENTAL

Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation

Intervention Type PROCEDURE

Pulmonary vein isolation is performed via transseptal access to the left atrium using a point-by-point bipolar pulsed-field ablation catheter

Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion

Intervention Type PROCEDURE

Targeted application of radiofrequency energy at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical location of the superior paraseptal parasympathetic ganglion.

Standard PFA pulmonary vein isolation

Participants will undergo pulmonary vein isolation using the same point-by-point bipolar PFA system without any additional thermal applications.

Group Type ACTIVE_COMPARATOR

Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation

Intervention Type PROCEDURE

Pulmonary vein isolation is performed via transseptal access to the left atrium using a point-by-point bipolar pulsed-field ablation catheter

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pulmonary Vein Isolation using Point-by-Point Bipolar Pulsed-Field Ablation

Pulmonary vein isolation is performed via transseptal access to the left atrium using a point-by-point bipolar pulsed-field ablation catheter

Intervention Type PROCEDURE

Selective Radiofrequency Ablation of the Superior Paraseptal Parasympathetic Ganglion

Targeted application of radiofrequency energy at the anterior aspect of the right superior pulmonary vein, corresponding to the anatomical location of the superior paraseptal parasympathetic ganglion.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* Documented paroxysmal atrial fibrillation (AF) lasting ≥30 seconds on ECG or Holter monitoring
* Willingness and ability to provide written informed consent
* Life expectancy \>1 year

Exclusion Criteria

* Persistent AF lasting \>7 days or long-standing AF \>1 year
* Secondary AF due to electrolyte imbalance, thyroid disease, alcohol abuse, or other non-cardiac causes
* Left atrial anteroposterior diameter ≥45 mm on transthoracic echocardiography
* Clinically significant coexisting arrhythmias other than AF
* Significant valvular heart disease or valve prosthesis
* Chronic heart failure NYHA class III/IV
* Previous AF or atrial flutter ablation
* Prior closure of atrial septal defect or left atrial appendage
* Atrial myxoma
* Implanted pacemaker or defibrillator
* History of pericarditis
* Congenital heart disease
* Coagulopathy or bleeding disorders
* Contraindications to oral anticoagulation
* Contraindications to CT or MRI
* Pregnancy or breastfeeding
* Body Mass Index \>30
* History of organ transplantation
* Severe pulmonary disease
* Estimated Glomerular Filtration Rate \<30 mL/min/1.73 m²
* Active malignancy
* Significant infection
* Life expectancy \<1 year
* Psychiatric disorders preventing study participation
* Refusal or inability to provide informed consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Joseph's Centre, Poland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Łukasz Zarębski

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

St. Joseph's Heart Rhythm Center

Rzeszów, Podkarpackie Voivodeship, Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Piotr Futyma, MD, PhD

Role: CONTACT

+48 17 858 19 00

Łukasz Zarębski, MD

Role: CONTACT

+48 17 858 19 00

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Piotr Futyma, MD, PhD

Role: primary

+48 533 503 044

Łukasz Zarębski, MD

Role: backup

+48 17 858 19 00

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12/2025/B

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.